RecruitingNCT06305468

Prognosis of Disseminated and Cerebral Toxoplasmosis Hospitalized in Intensive Care in the Era of PCR Diagnosis

Prognosis of Disseminated and Cerebral Toxoplasmosis Hospitalized in Intensive Care in the Era of PCR Diagnosis - Toxoplasmosis in ICU (TOXIC)


Sponsor

Assistance Publique - Hôpitaux de Paris

Enrollment

200 participants

Start Date

Aug 1, 2024

Study Type

OBSERVATIONAL

Conditions

Summary

Toxoplasmosis is a common infection whose clinical severity can sometimes justify admission to intensive care, especially in immunocompromised patients. This study should make it possible to evaluate the impact of different anti-infective treatment regimens and to highlight clinical-biological and prognostic differences depending on the type of underlying immunosuppression.


Eligibility

Min Age: 18 YearsMax Age: 100 Years

Inclusion Criteria3

  • Adult patient hospitalized in intensive care
  • At least 1 organ failure (SOFA> or =2)
  • PCR toxoplasmosis on CSF, blood, BAL, or bone marrow positive within 7 days before or after admission to ICU

Exclusion Criteria3

  • Post-mortem diagnosis
  • Primary outcome not available
  • Patient living informed and not opposed to the reuse of their data in this research.

Interested in this trial?

Get notified about updates and connect with the research team.


Locations(1)

Cochin hospital

Paris, France, France

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06305468


Related Trials